Lymphocyte and monocyte subtypes in coronary artery ectasia patients

doi:10.16138/j.1673-6087.2022.05.005

Abstract

Abstract:

Objective To determine whether peripheral lymphocytes and monocytes were involved in the pathological processes of coronary artery ectasia (CAE). Methods This study included 34 patients who underwent coronary angiography and were diagnosed as CAE from January 2017 to January 2018. In addition, a total of 30 patients with coronary heart disease (CHD) and 32 subjects with relatively normal coronary arteries (control group) who underwent coronary angiography on the same period were included by lot. Three groups were balanced according to age, sex, and other baseline characteristics, and the lymphocyte and monocyte subtypes in their blood samples were examined via flow cytometry. Results Lymphocyte subtypes in CAE and CHD patients showed no significant differences. However, compared to the CHD and control groups, the inflammatory (non-classic type) monocytes were significantly increased [26.45% (16.90%-44.55%) vs 13.70%(9.33%-17.60%), or 7.00% (13.70%-29.40%), P=0.000], while the classic subtype monocytes were significantly decreased [66.35% (39.73%-78.83%) vs 82.90% (80.50%-89.40%) or 78.30% (56.70%-83.80%), P=0.000] in the CAE group. Multiple linear regression analysis further confirmed that the non-classic monocyte was related to CAE [CAE group=1, CHD group=2, control group=3, so the regression coefficient is negative as β=-0.371, P=0.000 ]. Conclusions CAE could be an inflammatory disease rather than an immune disease.

Key words: Coronary artery ectasia, Lymphocyte, Monocyte, Inflammation

CLC Number:

R543.3

LIU Ruifeng, SHENG Qianqian, ZHANG Yue, ZHAO Huiqiang. Lymphocyte and monocyte subtypes in coronary artery ectasia patients[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 373-378.

Figures/Tables 5

References 24

[1]	Sheikh AS, Hailan A, Kinnaird T, et al. Coronary artery aneurysm: evaluation, prognosis, and proposed treatment strategies[J]. Heart Views, 2019, 20(3): 101-108. doi: 10.4103/HEARTVIEWS.HEARTVIEWS_1_19 pmid: 31620255
[2]	Eitan A, Roguin A. Coronary artery ectasia: new insights into pathophysiology, diagnosis, and treatment[J]. Coron Artery Dis, 2016, 27(5): 420-428. doi: 10.1097/MCA.0000000000000379 URL
[3]	Markis JE, Joffe CD, Cohn PF, et al. Clinical significance of coronary arterial ectasia[J]. Am J Cardiol, 1976, 37(2): 217-222. pmid: 1108631
[4]	Li JJ, He JG, Nan JL, et al. Is systemic inflammation responsible for coronary artery ectasia?[J]. Int J Cardiol, 2008, 130(2): e69-e70. doi: 10.1016/j.ijcard.2007.11.078 URL
[5]	Balta S, Demir M, Ozturk C, et al. The relation between inflammation and coronary artery ectasia[J]. Rev Port Cardiol, 2016, 35(10): 553-554. doi: 10.1016/j.repc.2016.04.011 pmid: 27637373
[6]	Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients[J]. Cytometry A, 2020, 97(8): 772-776. doi: 10.1002/cyto.a.24172 URL
[7]	Cormican S, Griffin MD. Human monocyte subset distinctions and function[J]. Front Immunol, 2020, 11: 1070. doi: 10.3389/fimmu.2020.01070 pmid: 32582174
[8]	Tamis-Holland JE, Jneid H, Reynolds HR, et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease[J]. Circulation, 2019, 139(18): e891-e908. doi: 10.1161/CIR.0000000000000670
[9]	Lin JP, Vitek L, Schwertner HA. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease[J]. Clin Chem, 2010, 56(10): 1535-1543. doi: 10.1373/clinchem.2010.151043 URL
[10]	Tsai WN, Wang YY, Liang JT, et al. Serum total bilirubin concentrations are inversely associated with total white blood cell counts in an adult population[J]. Ann Clin Biochem, 2015, 52 Pt2: 251-258.
[11]	Turhan H, Erbay AR, Yasar AS, et al. Impaired coronary blood flow in patients with metabolic syndrome[J]. Am Heart J, 2004, 148(5): 789-794. pmid: 15523308
[12]	李彭军, 韩慧文, 葛兰, 等. 健康体检者循环单核细胞亚群与性别及年龄的关系[J]. 武警医学, 2014, 25(1): 5-8.
[13]	Chen J, Zhang Y, Liu J, et al. Role of lipoprotein(a) in predicting the severity of new on-set coronary artery disease in type 2 diabetics[J]. Diab Vasc Dis Res, 2015, 12(4): 258-264. doi: 10.1177/1479164115579004 URL
[14]	Matta AG, Yaacoub N, Nader V, et al. Coronary artery aneurysm[J]. World J Cardiol, 2021, 26, 13(9): 446-455.
[15]	Sheikh AS, Hailan A, Kinnaird T, et al. Coronary artery aneurysm: evaluation, prognosis, and proposed treatment strategies[J]. Heart Views, 2019, 20(3): 101-108. doi: 10.4103/HEARTVIEWS.HEARTVIEWS_1_19 pmid: 31620255
[16]	Virmani R, Robinowitz M, Atkinson JB, et al. Acquired coronary arterial aneurysms[J]. Hum Pathol, 1986, 17(6): 575-583. pmid: 3710470
[17]	Sarli B, Baktir AO, Saglam H, et al. Neutrophil-to-lymphocyte ratio is associated with severity of coronary artery ectasia[J]. Angiology, 2014, 65(2): 147-151. doi: 10.1177/0003319713488932 pmid: 23657176
[18]	Li JJ, Nie SP, Qian XW, et al. Chronic inflammatory status in patients with coronary artery ectasia[J]. Cytokine, 2009, 46(1): 61-64. doi: 10.1016/j.cyto.2008.12.012 URL
[19]	Iwańczyk S, Borger M, Kamiński M, et al. Inflammatory response in patients with coronary artery ectasia and coronary artery disease[J]. Kardiol Pol, 2019, 77(7-8): 713-715. doi: 10.33963/KP.14812 pmid: 31066726
[20]	Lamblin N, Bauters C, Hermant X, et al. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease[J]. J Am Coll Cardiol, 2002, 40(1): 43-48. pmid: 12103254
[21]	Finkelstein A, Michowitz Y, Abashidze A, et al. Temporal association between circulating proteolytic, inflammatory and neurohormonal markers in patients with coronary ectasia[J]. Atherosclerosis, 2005, 179(2): 353-359. pmid: 15777553
[22]	Lee NY, Park HY, Park CK, et al. Analysis of systemic endothelin-1, matrix metalloproteinase-9, macrophage chemoattractant protein-1, and high-sensitivity C-reactive protein in normal-tension glaucoma[J]. Curr Eye Res, 2012, 37(12): 1121-1126. doi: 10.3109/02713683.2012.725798 pmid: 22966842
[23]	Liu R, Chen L, Wu W, et al. Neutrophil serine proteases and their endogenous inhibitors in coronary artery ectasia patients[J]. Anatol J Cardiol, 2016, 16(1): 23-28. doi: 10.5152/akd.2015.6072 pmid: 26467359
[24]	Katritsis DG, Zografos T, Korovesis S, et al. Antiendothelial cell antibodies in patients with coronary artery ectasia[J]. Coron Artery Dis, 2010, 21(16): 352-356. doi: 10.1097/MCA.0b013e32833d5fae URL

指标	对照组（n=32）	CHD组（n=30）	CAE组（n=34）	F/χ²/Z	P
年龄（岁）	60.53±5.22	63.43±6.75	63.53±8.42	1.818	0.168
男性[n（%）]	17(56.7)	18(60.0)	19(63.3)	0.870	0.870
高血压[n（%）]	21(70.0)	26(86.7)	26(86.7)	0.174	0.174
收缩压（mmHg）	121.30±13.04	129.28±19.51	124.57±14.6	1.870	0.160
舒张压（mmHg）	72.83±8.47	77.14±19.19	75.37±11.94	0.720	0.490
糖尿病[n（%）]	4(13.3)	14(46.7)	20(66.7)	0.000	0.000
糖化血红蛋白（%）	5.98±0.96	6.64±1.22	6.37±1.06	2.522	0.087
吸烟[n（%）]	15(50.0)	13(43.3)	14(46.7)	0.866	0.865
饮酒[n（%）]	10(33.3)	11(36.7)	5(16.7)	0.216	0.216
CHD家族史[n（%）]	5(16.6)	12(40.0)	9(30.0)	0.134	0.134
高血压家族史[n（%）]	8(26.7)	14(46.7)	7(23.3)	0.127	0.127
BMI（kg/m²）	27.00(24.30, 29.00)	26.30(23.81, 27.66)	27.00(25.25, 28.07)	0.413	0.285
ALT（U/L）	23.10(16.50, 27.50)	18.00(13.00, 21.00)	17.00(12.00, 32.00)	2.916	0.066
AST（U/L）	19.60(16.00, 23.00)	18.65(15.00, 23.00)	18.70(17.35, 21.70)	2.690	0.543
尿素氮（mmol/L）	74.90(69.20, 89.50)	82.80(70.50, 88.40)	78.90(66.33, 91.53)	0.193	0.796
血肌酐（μmol/L）	4.82(4.16, 6.18)	5.41(4.51, 6.27)	5.07(4.13, 6.86)	0.579	0.577
TC（mmol/L）	4.31(3.47, 4.79)	3.85(3.36, 4.85)	3.85(3.42, 4.84)	0.075	0.743
TG（mmol/L）	1.40(0.88, 2.52)	1.50(1.07, 1.82)	1.42(1.04, 1.90)	0.185	0.942
HDL-C（mmol/L）	1.11(0.87, 1.36)	1.01(0.87, 1.28)	0.95(0.82, 1.14)	2.372	0.147
LDL-C（mmol/L）	2.25(1.73, 2.70)	2.07(1.85, 2.60)	2.06(1.77, 2.70)	0.374	0.858

指标	对照组（n=32）	CHD组（n=30）	CAE组（n=34）	F/χ²/Z	P
白细胞（×10⁹/L）	6.52±1.43	7.22±2.02	6.72±1.37	1.455	0.239
淋巴细胞（×10⁹/L）	1.85±0.53	1.88±0.53	1.97±0.02	0.429	0.652
单核细胞（×10⁹/L）	0.42±0.12	0.41±0.13	0.41±0.13	0.001	0.999
中性粒细胞（×10⁹/L）	4.09±1.19	4.72±1.89	4.27±1.03	1.583	0.211
NL比值	2.40±1.03	2.69±1.28	2.30±0.781	1.185	0.324
嗜碱性粒细胞（×10⁹/L）	0.04±0.02	0.04±0.02	0.04±0.02	0.292	0.747
嗜酸性粒细胞（×10⁹/L）	0.137±0.066	0.154±0.139	0.128±0.086	0.500	0.608
hs-CRP（mg/L）	1.29(0.46, 1.61)	1.50(0.80, 3.07)	1.30(0.68, 3.59)	0.497	0.339
ESR（mm/1h）	7.00(4.00, 9.50)	8.50(6.75, 12.25)	9.00(6.00, 15.00)	0.892	0.190
总胆红素（mmol/L）	12.98(9.98, 16.00)	12.63(10.30, 17.32)	13.81(11.09, 17.91)	0.776	0.470
直接胆红素（mmol/L）	2.05(1.69, 3.13)	2.52(1.69, 2.99)	2.57(1.98, 3.38)	0.092	0.685
间接胆红素（mmol/L）	10.09(7.87, 14.21)	10.03(7.79, 14.25)	10.92(8.82, 14.18)	0.344	0.452
左主干狭窄[n（%）]	-	3(10.0)	0(0.0)	3.450	0.063
前降支狭窄[n（%）]	-	25(83.3)	29(85.3)	0.249	0.618
回旋支狭窄[n（%）]	-	21(70.0)	19(55.9)	0.964	0.326
右冠脉狭窄[n（%）]	-	21(70.0)	26(76.5)	0.671	0.432
Gensini评分	-	39.00(34.50, 54.00)	36.50(31.00, 59.25)	-0.828	0.408
前降支的TFC（帧）	28.00(23.00, 35.00)	28.00(22.00, 39.00)	39.50(33.00, 48.25)	17.388	0.000
回旋支的TFC（帧）	30.00(23.00, 33.00)	25.00(19.00, 37.00)	37.50(28.75, 52.25)	11.098	0.000
右冠脉的TFC（帧）	25.00(20.00, 30.00)	21.00(18.00, 31.00)	30.00(24.00, 44.00)	10.529	0.002
左主干扩张[n（%）]	-	-	7(20.6)		-
前降支扩张[n（%）]	-	-	19(55.9)		-
回旋支扩张[n（%）]	-	-	16(47.1)		-
右冠脉扩张[n（%）]	-	-	26(76.5)		-

指标	对照组（n=32）	CHD组（n=30）	CAE组（n=34）	P	P1	P2	P3
CD3⁺CD4⁺淋巴细胞	41.10(26.70, 52.30)	60.20(51.30, 72.83)	58.30(47.45, 68.10)	0.000	0.371	0.000	0.000
CD3⁺CD8⁺淋巴细胞	24.30(18.10, 30.60)	28.10(22.78, 34.65)	31.25(23.23, 37.95)	0.091	0.371	0.039	0.147
CD16⁺淋巴细胞	13.20(8.35, 21.60)	18.00(11.10, 21.70)	14.90(10.53, 20.90)	0.215	0.386	0.398	0.076
CD19⁺淋巴细胞	3.02(1.30, 5.26)	4.67(1.92, 6.70)	3.02(1.81, 8.17)	0.349	0.545	0.479	0.128
经典型单核细胞	78.30(56.70, 83.80)	82.90(80.50, 89.40)	66.35(39.73, 78.83)	0.000	0.000	0.060	0.006
中间型单核细胞	1.03(0.35, 5.94)	0.00(0.00, 0.00)	1.47(0.22, 3.76)	0.000	0.000	0.497	0.000
非经典型单核细胞	17.00(13.70, 29.40)	13.70(9.33, 17.60)	26.45(16.90, 44.55)	0.000	0.000	0.046	0.015

项目	β	95%置信区间		标准化β	t	P
常数	79.011	23.378	134.643		2.889	0.007
组别（CAE组=1,CHD组=2,对照组=3）	-8.589	-16.284	-0.894	-0.371	-2.271	0.030
高血压（无=0, 有=1）	-24.608	-42.003	-7.214	-0.494	-2.878	0.007
中性粒细胞	4.650	1.095	8.205	0.412	2.661	0.012
ESR	0.732	0.124	1.339	0.386	2.451	0.020
Gensini评分	-0.278	-0.556	-0.001	-0.332	-2.040	0.049